You just read:

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Feb 20, 2013, 05:00 ET